KONINKLIJKE PHILIPS NV (PHI1.DE) Fundamental Analysis & Valuation

FRA:PHI1 • NL0000009538

Current stock price

23.79 EUR
-0.4 (-1.65%)
Last:

This PHI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. PHI1.DE Profitability Analysis

1.1 Basic Checks

  • PHI1 had positive earnings in the past year.
  • PHI1 had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
  • PHI1 had a positive operating cash flow in 4 of the past 5 years.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B

1.2 Ratios

  • With a Return On Assets value of 3.32%, PHI1 perfoms like the industry average, outperforming 47.54% of the companies in the same industry.
  • PHI1's Return On Equity of 8.17% is fine compared to the rest of the industry. PHI1 outperforms 60.66% of its industry peers.
  • PHI1's Return On Invested Capital of 5.16% is in line compared to the rest of the industry. PHI1 outperforms 47.54% of its industry peers.
  • PHI1 had an Average Return On Invested Capital over the past 3 years of 3.27%. This is significantly below the industry average of 10.31%.
  • The last Return On Invested Capital (5.16%) for PHI1 is above the 3 year average (3.27%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROIC 5.16%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.27%
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • PHI1 has a Profit Margin (5.02%) which is comparable to the rest of the industry.
  • PHI1's Profit Margin has declined in the last couple of years.
  • The Operating Margin of PHI1 (7.98%) is comparable to the rest of the industry.
  • PHI1's Operating Margin has declined in the last couple of years.
  • PHI1 has a worse Gross Margin (45.18%) than 75.41% of its industry peers.
  • PHI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
OM growth 3YN/A
OM growth 5Y-5.27%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. PHI1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHI1 is destroying value.
  • The number of shares outstanding for PHI1 has been increased compared to 1 year ago.
  • PHI1 has more shares outstanding than it did 5 years ago.
  • PHI1 has a worse debt/assets ratio than last year.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • An Altman-Z score of 2.00 indicates that PHI1 is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of PHI1 (2.00) is worse than 60.66% of its industry peers.
  • The Debt to FCF ratio of PHI1 is 16.37, which is on the high side as it means it would take PHI1, 16.37 years of fcf income to pay off all of its debts.
  • PHI1 has a Debt to FCF ratio of 16.37. This is in the lower half of the industry: PHI1 underperforms 60.66% of its industry peers.
  • PHI1 has a Debt/Equity ratio of 0.63. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • The Debt to Equity ratio of PHI1 (0.63) is worse than 70.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Altman-Z 2
ROIC/WACC0.84
WACC6.16%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • PHI1 has a Current ratio of 1.32. This is in the lower half of the industry: PHI1 underperforms 62.30% of its industry peers.
  • A Quick Ratio of 0.94 indicates that PHI1 may have some problems paying its short term obligations.
  • PHI1's Quick ratio of 0.94 is on the low side compared to the rest of the industry. PHI1 is outperformed by 63.93% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.94
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PHI1.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.11% over the past year.
  • PHI1 shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -6.62% yearly.
  • PHI1 shows a decrease in Revenue. In the last year, the revenue decreased by -1.03%.
  • The Revenue has been growing slightly by 0.59% on average over the past years.
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-1.03%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%

3.2 Future

  • PHI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.24% yearly.
  • The Revenue is expected to grow by 3.78% on average over the next years.
EPS Next Y3.11%
EPS Next 2Y8.19%
EPS Next 3Y10.16%
EPS Next 5Y10.24%
Revenue Next Year1.44%
Revenue Next 2Y2.95%
Revenue Next 3Y3.5%
Revenue Next 5Y3.78%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. PHI1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 16.18 indicates a correct valuation of PHI1.
  • Compared to the rest of the industry, the Price/Earnings ratio of PHI1 indicates a rather cheap valuation: PHI1 is cheaper than 88.52% of the companies listed in the same industry.
  • PHI1's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.47.
  • The Price/Forward Earnings ratio is 15.69, which indicates a correct valuation of PHI1.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PHI1 indicates a somewhat cheap valuation: PHI1 is cheaper than 67.21% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.62. PHI1 is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 16.18
Fwd PE 15.69
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHI1 is valued a bit cheaper than the industry average as 73.77% of the companies are valued more expensively.
  • PHI1's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 46.37
EV/EBITDA 11.21
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)5.2
PEG (5Y)N/A
EPS Next 2Y8.19%
EPS Next 3Y10.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHI1.DE Dividend Analysis

5.1 Amount

  • PHI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHI1.DE Fundamentals: All Metrics, Ratios and Statistics

KONINKLIJKE PHILIPS NV

FRA:PHI1 (4/23/2026, 7:00:00 PM)

23.79

-0.4 (-1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-06
Inst Owners48.33%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap22.91B
Revenue(TTM)17.84B
Net Income(TTM)895.00M
Analysts74.67
Price Target29.06 (22.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.35
Dividend Growth(5Y)216.55%
DP36.65%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.02%
Min EPS beat(2)3.95%
Max EPS beat(2)14.1%
EPS beat(4)4
Avg EPS beat(4)17.83%
Min EPS beat(4)3.95%
Max EPS beat(4)31.04%
EPS beat(8)4
Avg EPS beat(8)2.84%
EPS beat(12)6
Avg EPS beat(12)6.47%
EPS beat(16)7
Avg EPS beat(16)6.93%
Revenue beat(2)0
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-2.4%
Max Revenue beat(2)-0.86%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)-0.86%
Revenue beat(8)0
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.36%
Revenue beat(16)2
Avg Revenue beat(16)-1.72%
PT rev (1m)-0.78%
PT rev (3m)7.34%
EPS NQ rev (1m)-4.65%
EPS NQ rev (3m)-35.78%
EPS NY rev (1m)-0.89%
EPS NY rev (3m)-0.71%
Revenue NQ rev (1m)-0.63%
Revenue NQ rev (3m)5.4%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-1.26%
Valuation
Industry RankSector Rank
PE 16.18
Fwd PE 15.69
P/S 1.28
P/FCF 46.37
P/OCF 19.71
P/B 2.09
P/tB N/A
EV/EBITDA 11.21
EPS(TTM)1.47
EY6.18%
EPS(NY)1.52
Fwd EY6.37%
FCF(TTM)0.51
FCFY2.16%
OCF(TTM)1.21
OCFY5.07%
SpS18.52
BVpS11.38
TBVpS-0.92
PEG (NY)5.2
PEG (5Y)N/A
Graham Number19.4007 (-18.45%)
Profitability
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROCE 7.33%
ROIC 5.16%
ROICexc 6.02%
ROICexgc 20.88%
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
FCFM 2.77%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.27%
ROIC(5y)N/A
ROICexc(3y)3.74%
ROICexc(5y)N/A
ROICexgc(3y)12.88%
ROICexgc(5y)N/A
ROCE(3y)4.66%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.19%
ROICexc growth 3YN/A
ROICexc growth 5Y-4.56%
OM growth 3YN/A
OM growth 5Y-5.27%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Debt/EBITDA 2.72
Cap/Depr 59.38%
Cap/Sales 3.75%
Interest Coverage 5.63
Cash Conversion 45.59%
Profit Quality 55.2%
Current Ratio 1.32
Quick Ratio 0.94
Altman-Z 2
F-Score7
WACC6.16%
ROIC/WACC0.84
Cap/Depr(3y)53.03%
Cap/Depr(5y)53.41%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
EPS Next Y3.11%
EPS Next 2Y8.19%
EPS Next 3Y10.16%
EPS Next 5Y10.24%
Revenue 1Y (TTM)-1.03%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%
Revenue Next Year1.44%
Revenue Next 2Y2.95%
Revenue Next 3Y3.5%
Revenue Next 5Y3.78%
EBIT growth 1Y15922.2%
EBIT growth 3YN/A
EBIT growth 5Y-4.71%
EBIT Next Year68.02%
EBIT Next 3Y26.32%
EBIT Next 5Y17.86%
FCF growth 1Y-43.86%
FCF growth 3YN/A
FCF growth 5Y-22.31%
OCF growth 1Y-25.32%
OCF growth 3YN/A
OCF growth 5Y-15.14%

KONINKLIJKE PHILIPS NV / PHI1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


What is the profitability of PHI1 stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 4 / 10.


What is the financial health of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 1 / 10.


Can you provide the expected EPS growth for PHI1 stock?

The Earnings per Share (EPS) of KONINKLIJKE PHILIPS NV (PHI1.DE) is expected to grow by 3.11% in the next year.